NasdaqCM - Delayed Quote USD

bioAffinity Technologies, Inc. (BIAFW)

0.1711

+0.0011

+(0.65%)

At close: April 25 at 4:00:00 PM EDT

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer

SAN ANTONIO, May 08, 2025--A newly released white paper shares four real-world cases where bioAffinity's CyPath® Lung played a pivotal role in guiding clinical decisions.

Business Wire 2 days ago

BIAF

BIAFW
+0.65%
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable

PR Newswire 3 days ago

BIAF

BIAFW
+0.65%
bioAffinity Technologies Announces Closing of $3.25 Million Offering

SAN ANTONIO, May 07, 2025--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million.

Business Wire 3 days ago

BIAF

BIAFW
+0.65%
BioAffinity Technologies announces pricing of $3.25M offering

WallachBeth Capital announced that bioAffinity Technologies (BIAF) priced a best efforts offering of securities for aggregate gross proceeds to the company of $3.25M, before deducting agent fees and other estimated expenses payable by the company. The offering consists of 10.16M shares of common stock together with warrants to initially purchase up to 15.23M shares of common stock. The combined public offering price for each share of common stock and accompanying warrant is 32c. The closing of t

TipRanks 3 days ago

BIAF

BIAFW
+0.65%
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, priced a best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company.

PR Newswire 4 days ago

BIAF

BIAFW
+0.65%
bioAffinity Technologies Announces Pricing of $3.25 Million Offering

SAN ANTONIO, May 06, 2025--bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million.

Business Wire 4 days ago

BIAF

BIAFW
+0.65%
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies

Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies are part of the Zacks top Analyst Blog.

Zacks 4 days ago

V

GOOG

BRK-B
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Berkshire Hathaway Inc. (BRK.B) and Visa Inc. (V), as well as a micro-cap stock bioAffinity Technologies, Inc. (BIAF).

Zacks 5 days ago

GOOG

V

BRK-B
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

SAN ANTONIO, April 17, 2025--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs.

Business Wire 23 days ago

BIAF

BIAFW
+0.65%
ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / April 17, 2025 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg ...

ACCESS Newswire 23 days ago

ASPI

BIAF

BIAFW
+0.65%
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues

bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.

Zacks last month

BIAFW
+0.65%

^GSPC
bioAffinity Technologies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

bioAffinity Technologies ( NASDAQ:BIAF ) Full Year 2024 Results Key Financial Results Revenue: US$9.36m (up 270% from...

Simply Wall St. last month

BIAF

BIAFW
+0.65%
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

SAN ANTONIO, March 31, 2025--bioAffinity Technologies, Inc. (BIAF) releases financial results for 2024.

Business Wire last month

BIAF

BIAFW
+0.65%
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

ACCESS Newswire last month

CANF

BIAF

BIAFW
+0.65%
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

SAN ANTONIO, March 26, 2025--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.

Business Wire last month

BIAF

BIAFW
+0.65%
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

SAN ANTONIO, March 19, 2025--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.

Business Wire last month

BIAF

BIAFW
+0.65%
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

SAN ANTONIO, March 13, 2025--Case studies highlight the benefit of CyPath Lung to both physicians and patients, including avoiding unnecessary invasive procedures.

Business Wire last month

BIAF

BIAFW
+0.65%
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

SAN ANTONIO, March 06, 2025--bioAffinity Technologies today announced strategic actions to cut $4 million in annual costs at its subsidiary CAP/CLIA pathology laboratory.

Business Wire 2 months ago

BIAF

BIAFW
+0.65%
WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company's shares of common stock (the "Existing Warrants"). In consideration for the immediate exercise in full

PR Newswire 2 months ago

BIAF

BIAFW
+0.65%
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

SAN ANTONIO, February 26, 2025--bioAffinity Technologies announces closing of warrant inducement transaction for aggregate gross proceeds of $1.4 million

Business Wire 2 months ago

BIAF

BIAFW
+0.65%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

bioAffinity Technologies, Inc. (BIAFW)

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Closing of $3.25 Million Offering

BioAffinity Technologies announces pricing of $3.25M offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies

Top Stock Reports for Alphabet, Berkshire Hathaway & Visa

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues

bioAffinity Technologies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million